Philip Moquist
Director Pfizer
Philip Moquist is a Director at Pfizer with deep expertise in medicinal and synthetic chemistry, specializing in ADCs. Over more than a decade at Seagen, he lead projects on novel payloads, auristatins, camptothecins, and linker technologies. His earlier experience includes research roles at the Broad Institute, focusing on small molecule optimization for cancer and infectious diseases, and postdoctoral work at the University of Münster on frustrated Lewis pair catalysis. Philip earned his PhD from Boston University, where he studied asymmetric catalysis, and began his career as a research associate at Kalypsys.
Seminars
- Rationally designing Auristatin S to improve the tolerability of auristatin payloads through the tuning of permeability and bystander activity
- Explaining how Auristatin S maintains key auristatin properties, including strong tubulin binding affinity and induction of immunogenic cell death
- Exploring Auristatin S improved preclinical therapeutic window
As the ADC field rapidly expands beyond the established topoisomerase-I paradigm into dual-payload constructs, bispecific formats, and entirely novel toxin classes, the safety assessment playbook must evolve. With no historical safety data to rely on and toxicity mechanisms that may be fundamentally different from traditional ADCs, developers face an urgent need to establish new frameworks for predicting and mitigating risk.
Join preclinical safety leaders from biotech and large pharma as they share strategies for de-risking the next generation of ADC innovation by:
- Designing fit-for-purpose toxicology packages for dual-payload ADCs, debating whether standard NHP studies are sufficient to detect additive or synergistic toxicities, and exploring how staggered-dosing studies and payload-selective biomarkers can deconvolute the contribution of each warhead to the overall safety profile
- Assessing the unique liabilities of bispecific and biparatopic formats, discussing how altered binding avidity, internalization kinetics, and tissue distribution create novel safety challenges that require bespoke in vitro and in vivo models to accurately predict clinical risk
- Prioritizing novel payload classes by mechanistic profiling, evaluating how a standardized preclinical safety screening cascade, encompassing human primary cell panels, tissue organoids, and computational modelling, can rapidly identify the most promising payloads with differentiated toxicity profiles before committing to costly IND-enabling studies
